公开(公告)号：US20230235076A1

公开(公告)日：2023-07-27

申请号：US18010858

申请日：2021-06-29

申请人： Glycotope GmbH

发明人： Antje DANIELCZYK ,  Johanna GELLERT ,  Anke FLECHNER ,  Patrik KEHLER

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61P35/00

CPC分类号： C07K16/2896 ,  A61K47/6849 ,  A61K47/6817 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/92 ,  C07K2317/73

摘要： The present invention pertains to humanized anti-Lewis Y antibodies which specifically bind to Lewis Y and do not show any cross-reactivity. Especially, the humanized anti-Lewis Y antibodies do not bind to Lewis b or any other blood group carbohydrate antigen. In particular, the present invention is directed to humanized anti-Lewis Y antibodies which are useful in the treatment of cancer.

公开(公告)号：US20210221910A1

公开(公告)日：2021-07-22

申请号：US17055303

申请日：2019-05-17

申请人： GLYCOTOPE GMBH

发明人： Johanna GELLERT ,  Anke FLECHNER ,  Doreen WEIGELT ,  Antje DANIELCZYK

IPC分类号： C07K16/30 ,  A61K47/68 ,  A61P35/02 ,  A61K39/395

摘要： The present disclosure pertains to novel antibodies directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody.